Prenetics Global (NASDAQ:PRE) CEO Buys $137,325.00 in Stock

Prenetics Global Limited (NASDAQ:PRE) CEO Danny Sheng Wu Yeung purchased 7,500 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were purchased at an average price of $18.31 per share, for a total transaction of $137,325.00. Following the completion of the purchase, the chief executive officer directly owned 95,235 shares of the company’s stock, valued at $1,743,752.85. This represents a 8.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Monday, August 24th, Danny Sheng Wu Yeung purchased 17,181 shares of Prenetics Global stock. The shares were purchased at an average price of $21.23 per share, with a total value of $364,752.63.

Prenetics Global Stock Performance

Shares of NASDAQ PRE traded up $1.62 during trading on Monday, reaching $21.82. The stock had a trading volume of 417,652 shares, compared to its average volume of 135,502. The company has a market cap of $368.19 million, a P/E ratio of -5.25 and a beta of 0.26. Prenetics Global Limited has a fifty-two week low of $7.18 and a fifty-two week high of $23.63. The business’s 50-day moving average price is $19.07 and its 200-day moving average price is $18.90.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The firm had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million. Analysts forecast that Prenetics Global Limited will post -1.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research note on Friday, July 17th. Wall Street Zen raised shares of Prenetics Global from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Benchmark increased their target price on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Prenetics Global has an average rating of “Moderate Buy” and an average target price of $34.25.

Institutional Investors Weigh In On Prenetics Global

Large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN acquired a new stake in Prenetics Global in the 4th quarter valued at about $47,000. State of Wyoming acquired a new position in shares of Prenetics Global during the first quarter worth about $48,000. JPMorgan Chase & Co. acquired a new position in shares of Prenetics Global during the third quarter worth about $65,000. Operose Advisors LLC purchased a new stake in shares of Prenetics Global during the second quarter worth approximately $129,000. Finally, Manatuck Hill Partners LLC purchased a new stake in shares of Prenetics Global during the fourth quarter worth approximately $170,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.